Novartis Unveils Promising Phase III Results for SMA Gene Therapy in Diverse Patient Population Novartis announces positive Phase III results for intrathecal onasemnogene abeparvovec, showing significant efficacy and safety in SMA patients. The findings mark a potential breakthrough treatment option.

Novartis Unveils Promising Phase III Results for SMA Gene Therapy in Diverse Patient Population #United_States #gene_therapy #East_Hanover #Novartis_SMA #OAV101_IT